Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2790)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5687)
  2. Department of Medicine (5677)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1020)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (663)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (196)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (121)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (413)
  4. Elsevier Science, Inc. (394)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5687)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC)
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D.; Runcie, K.; Zhang, T.; Gotto, G.; Merseburger, A. S.; Dos Santos, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC)
    Meeting Abstract

    Chablani, P. V.; Khaki, A. R.; Tawagi, K.; Grivas, P.; Hoffman-Censits, J.; Galsky, M. D.; Gupta, S.; Koshkin, V. S.; Plimack, E. R.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of (177)Lu-PSMA-617
    Meeting Abstract

    De Bono, J. S.; Morris, M. J.; Sartor, A. O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety
    Meeting Abstract

    Bryce, A. H.; McDermott, R. S.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial
    Meeting Abstract

    Ryan, C. J.; Kim, H.; Morris, M. J.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Sharifi, N.; Halabi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results
    Meeting Abstract

    Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Nowfar, S.; Einstein, D. J.; Martin, B.; Adorjan, P.; Dissanayake, M.; Verholen, F.; Gao, X.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Preferred treatment regimens for rare genitourinary (GU) malignancies
    Meeting Abstract

    Simon, N. I.; Berg, S. A.; Tan, A.; Chandran, E.; Atiq, S. O.; Kydd, A. R.; Cordes, L. M.; Mortazavi, A.; Reimers, M. A.; Milowsky, M. I.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A liquid biopsy-based proteomic assay to identify circulating tumor cell (CTC) -derived druggable targets in cancer patients
    Meeting Abstract

    Horrmann, A.; Arafa, A.; Kamalanathan, K.; Hesch, A.; Schaap, G.; Izuora, Z.; Ahmadi, M.; Konety, B. R.; Scher, H. I.; Antonarakis, E. S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies
    Meeting Abstract

    Shah, N. J.; Ravilla, R.; Osterland, A. J.; Todoroff, K.; Wang, C. Y.; Rane, P.; Saal, H.; Wang, D.; Motzer, R. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes
    Meeting Abstract

    Zarrabi, K. K.; Ababio, Y.; Eccleston, A.; Rao, Drnj; Kelly, S.; Chang, J. E.; Adejumo, K. L.; Lucht, S.; Paydar, C.; Van Doren, B. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save